NCT04908462View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
Autosomal Dominant Polycystic Kidney
Interventions
DRUG

AL01211 or Placebo (Part A)

Five dose groups with doses ranging from 2mg to 60 mg

DRUG

AL01211 or Placebo (Part B)

Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

AceLink Therapeutics, Inc.

INDUSTRY

NCT04908462 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers | Biotech Hunter | Biotech Hunter